Daily Summary of Health · Final editionFriday 20 November 2026 · UTC

Health News: 20 November 2026

Bayer Roundup deal, loss of measles-free status and Duchenne rejection lead health news

Bayer's up to $7.25 billion Roundup settlement and the loss of measles-free status in the US, Mexico and Bolivia were the day's main health developments. The FDA also rejected Capricor Therapeutics' Duchenne cell therapy after two randomized trials failed to show it delayed heart failure or preserved muscle function.

Illustration of the day's news: Bayer Roundup deal, loss of measles-free status and Duchenne rejection lead health newsIllustration
DS
Daily Summary Of Editors · How we summarise
16 stories20 sources
Image from Illustration: FDA rejects Capricor's Duchenne cell therapy deramiocelIllustration
01First reported

FDA rejects Capricor's Duchenne cell therapy deramiocel

The FDA rejected Capricor Therapeutics' deramiocel, a cell therapy for Duchenne muscular dystrophy, on Friday. The treatment was aimed at teenagers and young men who could no longer walk, a group with few options. Two randomized trials failed to show it delayed heart failure or preserved muscle function. The decision blocks the therapy from reaching the market.

Image from Illustration: Court approves up to $7.25B Bayer settlement over Roundup cancer claimsIllustration
02First reported

Court approves up to $7.25B Bayer settlement over Roundup cancer claims

A Missouri judge approved a nationwide settlement in which Bayer will pay up to $7.25 billion over two decades to resolve thousands of U.S. cancer claims over Roundup. The deal covers people already ill and future non-Hodgkin lymphoma diagnoses, with average payouts from $10,000 to $165,000 based on use, age and severity. Bayer denies Roundup causes cancer, and the settlement follows a Supreme Court ruling that weakened failure to warn claims.

Image from Illustration: Spectris Alzheimer's light and sound device misses main goal in pivotal trialIllustration
03First reported

Spectris Alzheimer's light and sound device misses main goal in pivotal trial

A 40 Hz light and sound Alzheimer's device called Spectris missed its primary endpoint in the HOPE trial, with no difference from sham on a composite measure at 12 months in 663 people with mild to moderate disease. A prespecified subgroup of 395 people with mild disease showed slower decline on some measures, including a 55.8% slowing in daily function scores. The findings suggest earlier treatment may matter.

Image from Illustration: US, Mexico and Bolivia lose measles-free statusIllustration
05First reported

US, Mexico and Bolivia lose measles-free status

The US, Mexico and Bolivia lost measles-free status this week after the same strain spread within their borders for over a year. Falling vaccination coverage, misinformation and pandemic disruptions are driving outbreaks, and a preliminary NEJM Evidence analysis found pregnant women face tenfold higher mortality risks from measles. In the US, more than 5,400 cases have been reported in 2026, with kindergarten MMR coverage at 92.4%.

Developing storyUS loses measles elimination statusFull timeline →
Image from Illustration: WHO warns smoking harms fertility for women and menIllustration
06First reported

WHO warns smoking harms fertility for women and men

A WHO report found smoking raises women's odds of infertility by 40% and is linked to erectile dysfunction, ejaculation problems, absent sperm, poor sperm movement and abnormal sperm shape in men. Secondhand smoke can lower the odds of having a child. Smoking by one partner could halve successful IVF pregnancy chances, and quitting lowers women's infertility odds by 25%.

Image from Illustration: Malaria antibody protects infants but lowers R21 vaccine responseIllustration
07First reported

Malaria antibody protects infants but lowers R21 vaccine response

A single dose of the experimental malaria antibody L9LS safely protected infants during Mali's six-month malaria season, with 78% efficacy against infection. However, it appeared to lower the immune response to the R21 malaria vaccine given afterward, so researchers are pausing plans for a larger infant trial. The antibody may still be explored for children who remain at risk after vaccination.

Image from Illustration: ERAS-0015 shrinks RAS-mutant lung and pancreatic tumours in phase I trialIllustration
08First reported

ERAS-0015 shrinks RAS-mutant lung and pancreatic tumours in phase I trial

Phase I results for ERAS-0015, a pan-RAS molecular glue, showed the drug was safe and shrank tumours in 148 patients with RAS-mutant cancers. It produced a 44% response rate in RAS-mutant pancreatic cancer and a 60% response rate in RAS-mutant lung cancer, with responses meaning considerable tumour shrinkage. The trial is evaluating the drug alone and in combination in several RAS-mutant solid tumours.

Image from Illustration: Study finds genetic markers for young-onset type 2 diabetes in a Chinese populationIllustration
09First reported

Study finds genetic markers for young-onset type 2 diabetes in a Chinese population

Researchers at the Chinese University of Hong Kong identified three genetic regions linked to younger onset of type 2 diabetes, impaired insulin-producing beta-cell function and poorer blood glucose control in a Chinese population. The team developed a genetic risk score for early, low-cost identification of high-risk individuals. Young-onset diabetes, diagnosed before age 40, accounts for one in five type 2 cases in Asia.

Image from Illustration: UnitedHealth sues to reverse downgraded Medicare Advantage star ratingsIllustration
10First reported

UnitedHealth sues to reverse downgraded Medicare Advantage star ratings

UnitedHealth Group sued the federal government to reverse lowered Medicare Advantage star ratings for 2027, becoming at least the 15th plan to challenge the Centers for Medicare and Medicaid Services. The largest Medicare Advantage insurer, covering more than 9 million people, says the ratings are inconsistent and push scores below the four-star bonus threshold. Medicare's annual enrollment period ends Dec. 7.

Image from Illustration: NHS patient horrified as therapy notes shared with 100,000 staffIllustration
11First reported

NHS patient horrified as therapy notes shared with 100,000 staff

The Information Commissioner's Office is investigating after a patient found that detailed psychotherapy notes about her grief and trauma had been uploaded to an NHS electronic record. The London Care Record was accessible to up to 140,000 NHS staff, and the notes had been shared with more than 100,000 NHS workers. South London and Maudsley NHS trust said key session content was automatically uploaded.

Image from Illustration: South Korea confirms first cholera case in 10 yearsIllustration
12First reported

South Korea confirms first cholera case in 10 years

South Korea reported its first cholera case in 10 years after health workers confirmed the infection in a person who visited an emergency room in Changwon earlier this month. The patient had vomiting and diarrhea, recovered and was discharged on Tuesday, and had not traveled overseas in the past two months. Health workers are tracing the source and contacts, and the agency urged people to use safe water and wash food properly.

Image from Illustration: Genetically engineered malaria vaccine shows 87% efficacy in phase 1 trialIllustration
13First reported

Genetically engineered malaria vaccine shows 87% efficacy in phase 1 trial

A genetically attenuated whole parasite malaria vaccine, PfSPZ-LARC2, achieved 87% efficacy in preventing infection in a phase 1 trial. Among 22 participants exposed to a controlled malaria challenge 12 to 16 weeks after their last dose, all seven placebo recipients became infected while only two of 15 vaccinated people did. The vaccine was safe and well tolerated.

Image from Illustration: Pancreatic cancer pill trial shows tumours vanish in some patientsIllustration
14First reported

Pancreatic cancer pill trial shows tumours vanish in some patients

A daily pill called daraxonrasib, given with chemotherapy, produced deep responses in early trials of advanced pancreatic cancer. Tumours stopped growing in almost all of the 61 participants, and cancer became undetectable on scans in one in 12. Just over 60% saw tumours shrink or disappear, but doctors said longer studies are needed to know whether the disease can be kept in remission.

Image from Illustration: Resident doctors in Northern Ireland begin 24-hour pay strikeIllustration
15First reported

Resident doctors in Northern Ireland begin 24-hour pay strike

Resident doctors in Northern Ireland began a 24-hour pay strike at 07:00 GMT, their second full-day action this year. The BMA rejected a recommended 3.5% rise and seeks pay restoration to 2008, while Health Minister Robbie Butler said he could not yet implement the award without a Stormont budget. Emergency care, urgent surgery and most GP services will continue, but many planned hospital appointments will be affected.

Image from Illustration: Big drugmakers say they will not start new China trial sites in XinjiangIllustration
16First reported

Big drugmakers say they will not start new China trial sites in Xinjiang

Five major drugmakers told a House Select Committee on China that they do not plan to start new clinical trial sites in Xinjiang or at hospitals affiliated with the Chinese military. The firms are Merck, Eli Lilly, AbbVie, Pfizer and Bristol Myers Squibb, investigated by the committee over intellectual property, military and ethical concerns. The committee said its letters noted rising security risks at trial sites in sensitive regions.